Maia Biotechnology

Maia Biotechnology is a public, Texas based, immune-oncology company.

Company
It is led by CEO/Chairman Vlad Vitoc, MD, MBA and Chief Scientific Officer Sergei M. Gryaznov, PhD. In August 2022, the company's initial funding round closed, raising $10M. In March 2024, the company's equity fell below .5 M, cause for delisting from NYSE. In April 2024 the company announced the completion of a $1M private placement.

Drug candidates
THIO (6-thio-2’-deoxyguanosine) is a drug that attempts to kill cells that express telomerase, which is found in 85% of human cancers.

Phase II THIO-101
A phase II THIO-101 clinical trial of THIO sequenced with cemiplimab to treat advanced non-small cell lung cancer (NSCLC). The trial is a multicentre, open-label, dose-finding trial designed to assess anti-tumour activity followed by PD-L1 inhibition. The study population was patients with advanced NSCLC who did not respond or developed resistance to first-line treatments using another checkpoint inhibitor. The trial's primary objectives are to assess tolerability, safety, and clinical efficacy using overall response rate (ORR) as the primary endpoint.